arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

UroGen Pharma Ltd.

URGN
$41.65 ▼ -1.09 (-2.55%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
38 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
65
Health
Good
Neutral
auto_awesome

Analytical Summary

UroGen Pharma Ltd. demonstrates solid fundamentals with strength in Return on Common Equity (%). However, watch Operating Margin (%) which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $2.1B
Dividend Yield
Revenue Growth 199.2%
Op. Margin 0.2%
ROIC 0.3%
FCF / Share $-0.66
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -1.51
info Valuation on last close. End-of-day price, Sep 23, 2026.

38-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$72.46M
↑ +199.2%
Net Income Profit after all expenses
$-14.35M
↑ +71.3%
Operating Margin Operating profit as % of sales
0.2%
↑ +100.4% 2th
FCF / Share Free cash flow per share
$-0.66
↑ +27.4%
Long-Term Debt Long-term obligations
$200.00M
— 0.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
2
Returns
100
Financial Health
100
Cash Quality
68

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 12 years · 38 quarters